Table 3.

Physician practices for the use of corticosteroids and primary prevention of vascular complications in TAK

Prednisone dose at diagnosis (mg/kg/day) for active disease	n (%)	Pharmacologic agents for primary prevention of vascular complications	n (%)
≤0.5	0	Antiplatelet agent	36 (90)
>0.5–<1	10 (25)	Duration of antiplatelet agent
1	26 (65)	First 6 months	3 (8)
>1	4 (10)	As long as possible	29 (78)
Duration of prednisone		As long as stenosis present	5 (14)
≤6 months	3 (8)	Lipid-lowering agents	9 (23)
6–12 months	16 (42)	ACE-I or ARB	4 (10)
12–24 months	10 (26)
Indefinitely	9 (23)

Abbreviations: ACE-I, angiotensin-converting enzyme inhibitor; ARB, angiotensin receptor blocker; TAK, Takayasu arteritis.